

## Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Integrated Care Partnership - Surrey Downs, Guildford & Waverley, North West Surrey, and East Surrey Places & associated partner organisations.

### Application for medicines described in CKS, NICE guidance and/or other national guidance

Name of guidance	<a href="#">Management of fibroids (Last revised April 2023)</a>
Available at	<a href="https://cks.nice.org.uk/topics/fibroids/management/management/">https://cks.nice.org.uk/topics/fibroids/management/management/</a>

The APC will have 4 options when asked to consider the application/s:

1. To accept
2. To reject
3. To allocate alternative traffic light classification
4. To request a full evidence review.

The traffic light status for the Surrey PAD is available at:



FINAL Sep-24 Colour  
classification guideline

Medicine name (generic and brand)	State licensed indication and if use in this application is licensed?	Place in therapy	Does it require dose titration?	Does it require monitoring? (SPC and SBS monitoring)	Recommended traffic light	<b>Comments</b> Must include information about: <ul style="list-style-type: none"> <li>• whether a cost impact is expected and by how much.</li> <li>• impact on workload, e.g. monitoring.</li> </ul>
<b>Tranexamic Acid tablets</b>	1 g three times daily for up to four days, to be initiated when menstruation has started. The dose may be increased to a maximum of 4 g daily.	Menorrhagia associated with fibroids	As per licence.	Close monitoring of patients with (or at risk of) haematuria of renal origin is recommended	<b>GREEN</b>	Capsules considered proposed non-formulary at October 2024 APC (more costly than tablets)
<b>Norethisterone (oral)</b>	5 mg three times daily) from day 5–26 of the menstrual cycle (the follicular and luteal phases)	Menorrhagia associated with fibroids	Off label		<b>GREEN</b>	Recommended alongside tranexamic acid as a treatment option for menorrhagia.
<b>Combined Hormonal Contraception</b>		Menorrhagia associated with fibroids			<b>GREEN</b>	For women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis

<p><b>levonorgestrel intrauterine system (LNG-IUS)</b></p>	<p>Benilexa, Mirena &amp; Levosert</p>	<p>Menorrhagia associated with fibroids</p>	<p>Licensed</p>		<p><b>GREEN</b></p>	<p><b>Benilexa and Levosert</b> Licensed for 3 years when used for menorrhagia</p> <p>Mirena Licensed for 5 years when used for menorrhagia</p>
<p><b>GnRH /LHRH analogues</b></p>	<p>Triptorelin (Decapeptyl SR® 3.75mg)</p>	<p>Treatment that would be initiated by a specialist team</p>	<p>N/A</p>	<p>Included in the Drug monitoring locally commissioned service (LCS) for the Administration of Care Closer to Home Drugs service. But funding not available in LCS budget because these treatments were not provided in primary care at the time of this proposal</p>	<p><b>RED</b></p>	<p>Reduction in size of uterine fibroids <b>Maximum duration of treatment should be 6 months.</b></p>
<p><b>GnRH/LHRH analogues</b></p>	<p>Leuprorelin (Prostap SR DCS®) 3.75mg</p>	<p>Treatment that would be initiated by a specialist team</p>	<p>N/A</p>	<p>Included in the Drug monitoring locally commissioned service (LCS) for the Administration of Care Closer to Home Drugs service. But funding not available in LCS budget because these treatments were not provided in primary care at the time of this proposal</p>	<p><b>RED</b></p>	<p>Preoperative management of uterine fibroids to reduce their size and associated bleeding. <b>Usually for 3-4 months but for a maximum of 6 months</b></p>

<b>GnRH/LHRH analogues</b>	Goserelin acetate (Zoladex® 3.6mg)	Treatment that would be initiated by a specialist team	N/A	Included in the Drug monitoring locally commissioned service (LCS) for the Administration of Care Closer to Home Drugs service. But funding not available in LCS budget because these treatments were not provided in primary care at the time of this proposal	<b>RED</b>	In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery. <b>May be administered for up to three months before surgery.</b>
<b>GnRH antagonist</b>	Relugolix/estradiol/norethisterone (Ryego®)	Traffic light status already determined at APC			<b>BLUE (initiation by specialist)</b>	
<b>Ulipristal acetate</b>	Esmya	MHRA warning <a href="https://www.gov.uk/drug-safety-update/ulipristal-acetate-5mg-esmya-further-restrictions-due-to-risk-of-serious-liver-injury">https://www.gov.uk/drug-safety-update/ulipristal-acetate-5mg-esmya-further-restrictions-due-to-risk-of-serious-liver-injury</a>			<b>NON-FORMULARY</b>	Traffic light status already defined in August 2021